Lung Cancer

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

Adding Keytruda to pre-surgical chemotherapy then giving it again after surgery improved event-free survival and pathologic complete response in patients with early-stage lung cancer.

The agency accepted a New Drug Application for repotrectinib, a TKI for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Watch Dr. Jyoti Malhotra and Ken Culver answer questions about the future of the disease during the CURE® Educated Patient® Lung Cancer Summit.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced non-small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Erminia Massarelli, from City of Hope National Medical Center, discuss advancements in early-stage non-small cell disease during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Ed Kim, Dr. Jyoti Malhotra and Terri Conneran answer questions about targeted therapy during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Jyoti Malhotra, from City of Hope Orange County, discuss targeted therapy, during the CURE® Educated Patient® Lung Cancer Summit.

Tagrisso plus chemotherapy improved progression-free survival in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer, according to high-level results from a phase 3 trial.

Watch an expert discuss biomarker testing during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Thomas Waddington and Dr. Percy Lee answer questions about diagnostic and radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Percy Lee, from City of Hope, discuss radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Thomas Waddington, from City of Hope National Medical Center, discuss the past and future of bronchoscopy during the CURE® Educated Patient® Lung Cancer Summit.

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.

The benefit derived from Tyvyt plus chemotherapy was present regardless of whether previously treated patients with EGFR-mutated, non-squamous non-small cell lung cancer also received Byvasda.

I’ve learned that knowledge is the key to fighting cancer. Here are three ways I learn more about my disease.

Deborah Lorick, M.S.N., M.H.A., RN, RNOCN, was the assistant nurse manager on the oncology unit where my husband was a patient. Deborah was always making sure that my husband, my children and I were well cared for.

The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.

Supportive care commonly addresses physical symptoms associated with lung cancer and side effects associated with cancer therapy.

The phase 3 Pragmatica-Lung study evaluating Cyramza and Keytruda has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

More awareness is needed to understand the benefits of both supportive care and palliative care in lung cancer.

For some patients with non-small cell lung cancer, removing part of the lobe rather than the entire lobe still provides benefit, study results show.

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

Treatment for patients with non-small cell lung cancer has evolved to include immunotherapy after surgery and chemotherapy.

Rybrevant outperformed other therapies for patients with exon 20 insertion-mutant, advanced non-small cell lung cancer in a clinical trial, highlighting the importance of personalized medicine.

Immunotherapy treatment with Opdivo before surgery improved recurrence-free survival and overall survival at five years in patients with non-small cell lung cancer.

The Food and Drug Administration will review Braftovi plus Mektovi for the treatment of patients with metastatic BRAF V600E-mutant non-small cell lung cancer.

Two-year follow-up data showed that Rybrevant was promising in a difficult-to-treat subtype of non-small cell lung cancer.